Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2022

View Archived Issues

CYSLTR1 blockade as a strategy to prevent breast cancer progression

Researchers identify DAW1 gene variants linked to motile ciliopathy

Design of a novel TAM inhibitor as a potential cancer therapy

Orion Corporation patents new CYP11A1 inhibitors

Wellstat Therapeutics divulges novel uridine derivatives

Eternity Bioscience synthesizes IRAK4 inhibitors

Vilnius University presents new carbonic anhydrase IX ligands

KalVista Pharmaceuticals patents FXIIa inhibitors

[68Ga]NOTA-cc90 demonstrates imaging of LAG-3 expression on tumor-infiltrating lymphocytes

FABP5 inhibitor ART26.12 shows promise for chemotherapy-induced pain

Ono and Fate Therapeutics expand drug discovery collaboration to include CAR-NK cell therapy

FDA clears IND for MALT1 inhibitor SGR-1505 for B-cell lymphomas

BiomX collaborates with Boehringer Ingelheim on biomarkers for IBD-associated pathogenic bacterium

Palleon and Henlius collaborate to codevelop bifunctional sialidase therapeutics

Series B financing at MiroBio funds development of checkpoint agonists to treat autoimmune diseases

miR-135b discriminates tongue cancer from noncancerous tissue

PDX models of radiation-resistant pediatric high-grade glioma show sensitivity to MAPK inhibition

Scorpion selects Exon 20 mutant EGFR inhibitor STX-721 as development candidate

Myelin-forming cells change in multiple brain diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...